Magellan Rx Management, a Prime Therapeutics company, Eagan, MN.
J Manag Care Spec Pharm. 2024 Apr;30(4):364-375. doi: 10.18553/jmcp.2024.30.4.364.
Social determinants of health (SDoH) are key factors that impact health outcomes. However, there are many barriers to collecting SDoH data (eg, cost of data collection, technological barriers, and lack of standardized measures). Population data may provide an accessible alternative to collecting SDoH data for patients.
To explain how population data can be leveraged to create SDoH measures, assess the association of population SDoH measures with diabetic medication adherence, and discuss how understanding a patient's SDoH can inform care plans and patient engagement.
A nationally representative commercial sample of patients who were aged 18 years and older and met Pharmacy Quality Alliance inclusion criteria for diabetes mellitus were analyzed (N = 37,789). US Census and North American Industry Classification System data were combined with pharmacy administrative claims data to create SDoH measures. Derived measures represent 2 SDoH domains: (1) economic stability (housing density, housing relocation, jobs per resident, and average salary) and (2) health care access and quality (urban/rural classification, distance traveled to prescriber and pharmacy, use of a primary care provider [PCP], and residents per PCP). The association of population SDoH measures with diabetic medication adherence (proportion of days covered) was assessed via logistic regression, which included covariates (eg, sex, age, comorbidities, and prescription plan attributes).
As housing density (houses per resident) increased, so did the likelihood of adherence (odds ratio = 1.54, 95% CI = 1.21-1.97, = 0.001). Relative to patients who did not move, patients who moved once had 0.87 (95% CI = 0.81-0.93, < 0.001) the odds of being adherent, and patients who moved 2 or more times had 0.82 (95% CI = 0.71-0.95, = 0.008) the odds of being adherent. Compared with areas with fewer jobs per resident, patients living within a zip code with 0.16 to 0.26 jobs per resident were 1.12 (95% CI = 1.04-1.20, = 0.002) times more likely to be adherent. Patients who lived in an urban cluster were 1.11 (95% CI = 1.01-1.22, = 0.037) times more likely to be adherent than patients living in a rural area. Patients who travel at least 25 miles to their prescriber had 0.82 (95% CI = 0.77-0.86, < 0.001) the odds of being adherent. Community pharmacy users had 0.65 (95% CI = 0.59-0.71, < 0.001) the odds of being adherent compared with mail order pharmacy users. Patients who had a PCP were 1.26 (95% CI = 1.18-1.34, < 0.001) times more likely to be adherent to their medication.
Leveraging publicly available population data to create SDoH measures is an accessible option to overcome barriers to SDoH data collection. Derived measures can be used to increase equity in care received by identifying patients who could benefit from assistance with medication adherence.
社会决定因素(SDoH)是影响健康结果的关键因素。然而,收集 SDoH 数据存在许多障碍(例如,数据收集成本、技术障碍和缺乏标准化措施)。人口数据可能是替代收集患者 SDoH 数据的一种可行方法。
解释如何利用人口数据来创建 SDoH 衡量标准,评估人口 SDoH 衡量标准与糖尿病药物依从性的关联,并讨论了解患者的 SDoH 如何为护理计划和患者参与提供信息。
分析了符合药房质量联盟糖尿病纳入标准的年龄在 18 岁及以上的全国性商业样本患者(N=37789)。将美国人口普查和北美行业分类系统数据与药房行政索赔数据相结合,创建 SDoH 衡量标准。衍生的衡量标准代表 2 个 SDoH 领域:(1)经济稳定性(住房密度、住房搬迁、每个居民的工作岗位和平均工资)和(2)医疗保健获取和质量(城乡分类、到医生和药房的旅行距离、使用初级保健提供者和每个医生的居民数量)。通过逻辑回归评估人口 SDoH 衡量标准与糖尿病药物依从性(覆盖率比例)的关联,其中包括协变量(例如,性别、年龄、合并症和处方计划属性)。
随着住房密度(每个居民的房屋数量)的增加,患者的依从性也随之增加(优势比=1.54,95%置信区间=1.21-1.97,P<0.001)。与没有搬家的患者相比,搬家一次的患者的依从性为 0.87(95%置信区间=0.81-0.93,P<0.001),搬家两次或更多次的患者的依从性为 0.82(95%置信区间=0.71-0.95,P=0.008)。与每个居民工作岗位较少的地区相比,居住在每个居民工作岗位在 0.16 到 0.26 之间的邮政编码地区的患者更有可能保持依从性,其比值比为 1.12(95%置信区间=1.04-1.20,P=0.002)。与居住在农村地区的患者相比,居住在城市集群中的患者更有可能保持依从性,其比值比为 1.11(95%置信区间=1.01-1.22,P=0.037)。到医生处至少旅行 25 英里的患者保持依从性的可能性为 0.82(95%置信区间=0.77-0.86,P<0.001)。与使用邮购药房的患者相比,社区药房使用者保持依从性的可能性为 0.65(95%置信区间=0.59-0.71,P<0.001)。有初级保健提供者的患者的依从性为 1.26(95%置信区间=1.18-1.34,P<0.001),是药物依从性的两倍。
利用公开可用的人口数据来创建 SDoH 衡量标准是克服 SDoH 数据收集障碍的一种可行方法。衍生的衡量标准可用于通过识别可能受益于药物依从性帮助的患者来提高获得的护理公平性。